Cleared Traditional

K042732 - ARCHITECT CA 15-3 ASSAY

K042732 is the FDA 510(k) clearance for ARCHITECT CA 15-3 ASSAY by Fujirebio Diagnostics,Inc.. It is a Class 2 Immunology device (product code MOI) cleared through the Traditional 510(k) pathway after a 82-day FDA review.

Download Printable Device Report (PDF)
Optimized for regulatory review, auditing and printing
Dec 2004
Decision
82d
Days
Class 2
Risk

K042732 is an FDA 510(k) clearance for the ARCHITECT CA 15-3 ASSAY. Classified as System, Test, Immunological, Antigen, Tumor (product code MOI), Class II - Special Controls.

Submitted by Fujirebio Diagnostics,Inc. (Malvern, US). The FDA issued a Cleared decision on December 22, 2004 after a review of 82 days - a notably fast clearance cycle.

This device falls under the Immunology FDA review panel, regulated under 21 CFR 866.6010 - the FDA immunology device framework. The Traditional 510(k) pathway establishes clearance through substantial equivalence to a legally marketed predicate device, without requiring clinical trial data.

Device pattern: Fast-track predicate clearance. Standard predicate reliance. The short review cycle indicates strong predicate alignment - the FDA found sufficient equivalence without extended technical review.

View all Fujirebio Diagnostics,Inc. devices

Submission Details

510(k) Number K042732 FDA.gov
FDA Decision Cleared Substantially Equivalent - Traditional 510(k) (SESE)
Date Received October 01, 2004
Decision Date December 22, 2004
Days to Decision 82 days
Submission Type Traditional
Review Panel Immunology (IM)
Summary Summary PDF
Third-party Review No - reviewed directly by FDA
Combination Product No
PCCP Authorized No
Regulatory Context
Review time vs. panel average
22d faster than avg
Panel avg: 104d · This submission: 82d
Pathway characteristics
Predicate-based equivalence. No clinical trials required.

Device Classification

Product Code MOI System, Test, Immunological, Antigen, Tumor
Device Class Class 2 - Special Controls
CFR Regulation 21 CFR 866.6010
What this classification means

Class II devices require demonstration of substantial equivalence to a legally marketed predicate device. This pathway does not require clinical trials - it relies on engineering equivalence and performance data. Most Immunology devices follow this clearance model.

Regulatory Peers - MOI System, Test, Immunological, Antigen, Tumor

All 18
Devices cleared under the same product code (MOI) and FDA review panel - the closest regulatory comparables to K042732.
Elecsys CA 15-3 II
K171605 · Roche Diagnostics · Feb 2018
DIMENSION VISTA LOCI CA 15-3 FLEX REAGENT CARTRIDGE, DIMENSION VISTA LOCI 7 CALIBRATOR, MODELS: K6456 AND KC605
K100344 · Siemens Healthcare Diagnostics · Apr 2011
ACCESS IMMUNOASSAY SYSTEMS BR MONITOR, AND CALIBRATORS, MODEL(S) 387620,AND 387647
K072612 · Beckman Coulter, Inc. · Oct 2007
BR MONITOR AND BR MONITOR CALIBRATORS ON THE ACCESS IMMUNOASSAY SYSTEMS, MODEL 387620, 387647
K033036 · Beckman Coulter, Inc. · Feb 2004
IMMULITE BR-MA, MODEL #LKBR
K013984 · Diagnostic Products Corp. · Mar 2002
AIA-PACK BRCA, ST AIA PACK BRCA
K010796 · Tosoh Medics, Inc. · Aug 2001